Here are three things to know:
1. Lattice Biologics’ Next Generation Allograft Technology is based on decellularized human Extracellular Matrix, a biological substrate for the company’s allografts.
2. The ECM-based allograft technology is derived from native ECM secreted by human mesenchymal stem cells.
3. The company’s allograft products are designed for several clinical applications, including enhancing spinal fusion.
More articles on biologics:
8 key surgeon Q&As on biologics in orthopedics & spine
International Stem Cell Corp. to launch joint supplement for osteoarthritis pain in Q3 2018
How Dr. Kevin Stone helped Super Bowl champion Tracy Porter make a comeback — 6 details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
